CA2668859A1 - Pyrimidine derivatives as posh and posh-ap inhibitors - Google Patents

Pyrimidine derivatives as posh and posh-ap inhibitors Download PDF

Info

Publication number
CA2668859A1
CA2668859A1 CA002668859A CA2668859A CA2668859A1 CA 2668859 A1 CA2668859 A1 CA 2668859A1 CA 002668859 A CA002668859 A CA 002668859A CA 2668859 A CA2668859 A CA 2668859A CA 2668859 A1 CA2668859 A1 CA 2668859A1
Authority
CA
Canada
Prior art keywords
compound
posh
polypeptide
virus
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002668859A
Other languages
English (en)
French (fr)
Inventor
Philippe Nakache
Itzchak Angel
Nurit Livnah
Maxim Borovitov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteologics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2668859A1 publication Critical patent/CA2668859A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002668859A 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors Abandoned CA2668859A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85737806P 2006-11-07 2006-11-07
US60/857,378 2006-11-07
US95983107P 2007-07-17 2007-07-17
US60/959,831 2007-07-17
PCT/IL2007/001356 WO2008056356A2 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors

Publications (1)

Publication Number Publication Date
CA2668859A1 true CA2668859A1 (en) 2008-05-15

Family

ID=39364907

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002668859A Abandoned CA2668859A1 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors

Country Status (6)

Country Link
US (2) US8283355B2 (https=)
EP (1) EP2083826A4 (https=)
JP (1) JP2010509205A (https=)
AU (1) AU2007318922C1 (https=)
CA (1) CA2668859A1 (https=)
WO (1) WO2008056356A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512234A (ja) * 2009-11-30 2013-04-11 プロテオロジクス リミテッド 小型ピリミジン誘導体およびその使用の方法
WO2013088445A1 (en) * 2011-12-13 2013-06-20 Proteologics Ltd Pyrimidine derivatives for treatment of inflammatory diseases
GB201415688D0 (en) * 2014-09-04 2014-10-22 Univ Edinburgh Method and Systems
JP6993318B2 (ja) * 2015-07-15 2022-02-03 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｂ型肝炎ウイルス複製の調節
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
EP3818051B1 (en) * 2018-07-05 2022-08-03 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
EP3949963A4 (en) * 2019-04-02 2023-01-04 Yonsei University, University-Industry Foundation(UIF). NEW COMPOUND AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING THIS AS AN ACTIVE PRINCIPLE
CN110760597B (zh) * 2019-11-22 2022-08-23 西北农林科技大学 一种检测黄牛ncstn基因拷贝数变异的方法及其应用
WO2025117616A1 (en) * 2023-11-27 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734081A (en) * 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
AU2002221565A1 (en) * 2000-12-08 2002-06-18 Novo-Nordisk A/S Trefoil factor 2 (tff2) peptides with moiety attached to asn15
FI116940B (fi) * 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
US7262185B2 (en) * 2001-08-08 2007-08-28 Takeda Chemical Industries Ltd. Benzazepine derivative, process for producing the same, and use
FR2845382A1 (fr) * 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
US8202861B2 (en) * 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US20050214751A1 (en) * 2004-03-02 2005-09-29 Proteologics, Inc. Inhibition of viral maturation, methods and compositions related thereto
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto

Also Published As

Publication number Publication date
EP2083826A2 (en) 2009-08-05
US8283355B2 (en) 2012-10-09
AU2007318922A1 (en) 2008-05-15
US20130131094A1 (en) 2013-05-23
WO2008056356A3 (en) 2009-09-03
WO2008056356A2 (en) 2008-05-15
EP2083826A4 (en) 2010-09-22
JP2010509205A (ja) 2010-03-25
AU2007318922C1 (en) 2013-09-12
US20100179178A1 (en) 2010-07-15
AU2007318922B2 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
US20130131094A1 (en) Pyrimidine derivatives as posh and posh-ap inhibitors
US9765019B2 (en) Small-molecule-targeted protein degradation
Agola et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition
US7659277B2 (en) Ubiquitin ligase inhibitors and methods related thereto
US7531320B2 (en) Modulation of β-catenin/TCF-activated transcription
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
Hao et al. Discovery, synthesis, and activity evaluation of novel five-membered sulfur-containing heterocyclic nucleosides as potential anticancer agents in vitro and in vivo
US20120015967A1 (en) Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors
JP2023541040A (ja) 筋ジストロフィーを処置するための組成物及び方法
US20050214751A1 (en) Inhibition of viral maturation, methods and compositions related thereto
WO2004078130A2 (en) Posh interacting proteins and related methods
AU2005279845A1 (en) Inhibition of viruses using RNase H inhibitors
US20060287337A1 (en) Trans-golgi network-associated processes, methods and compositions related thereto
Bao et al. Betulinic acid acetate, an antiproliferative natural product, suppresses client proteins of heat shock protein pathways through a CDC37-binding mechanism
US20060286630A1 (en) Posh interacting proteins and related methods
US20190352297A1 (en) Selective aurora a kinase inhibitors
Shouksmith Design and synthesis of small-molecule inhibitors targeting the SCFSKP2 E3 ligase and the MDMX-p53 interaction for cancer therapy
Quezada Meza PROTEIN KINASE CK2 IN HUMAN DISEASES: TOO MUCH OR TOO LITTLE?
하재영 Development and applications of thermal stability shift-based methodology for label-free target protein identification
WO2021183942A1 (en) Inhibitors of hsp70 proteins
Metwaly Drug Design and Development of Antivirals and Fluorescent Anion Transporters
WO2004098492A2 (en) Trans-golgi network-associated processes, methods and compositions related thereto
Sharma Strategic improvements in efficacy of DNA damaging chemotherapeutic drugs through modulation of survival factors
WO2009063412A1 (en) Use of chemical compounds for the treatment of aids

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150223